Baxter International Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the BAX Securities Class Action

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][3]. Allegations - The complaint states that Baxter failed to disclose systemic defects in the Novum LVP device, leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the device but did not take adequate remedial measures, leading to continued harm [3]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can choose to remain absent class members without participating in the case [5]. Company Background - Baxter International, Inc. is a global company that develops, manufactures, and markets medical products used in healthcare facilities [1].